A phase 3 study of ibrutinib in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously treated follicular lymphoma or marginal zone lymphoma.
Nathan Hale Fowler
Consultant or Advisory Role - Celgene; Gilead Sciences; Pharmacyclics; Roche
Research Funding - Celgene; Gilead Sciences; Janssen; Roche
Wolfgang Hiddemann
No relevant relationships to disclose
John Leonard
Consultant or Advisory Role - Pharmacyclics (U)
Esther Rose
Consultant or Advisory Role - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Tahamtan Ahmadi
Employment or Leadership Position - Janssen Research & Development
Jessica Vermeulen
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Janssen
Julie S. Larsen
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Janssen Pharmaceutical
Steven Sun
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Lisa Mentzer
No relevant relationships to disclose
Shean-Sheng Wang
Employment or Leadership Position - Janssen Pharmaceutical
Stock Ownership - Johnson & Johnson
Tzu-Min Yeh
Employment or Leadership Position - Janssen Research & Development
Stock Ownership - Johnson & Johnson
Gilles A. Salles
Consultant or Advisory Role - Janssen
Research Funding - Janssen